VPT:CC - Ventripoint Exhibiting at the American Society of Echocardiography 33rd Annual Scientific Session
(TheNewswire)
Toronto, Ontario – TheNewswire –June 7, 2022 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) is pleased to announce that it will be exhibitingand attending as a sponsor ( https://www.asescientificsessions.org/sponsors/ ) of the American Society of Echocardiography (ASE) 2022Conference titled “Sound Waves in Seattle: Connecting the World”.This is the 33 rd annual scientific session of the ASE and isbeing held in the Seattle Convention Center June 10-13, 2022.
The ASE is an organization ( https://www.asecho.org/about-ase/ ) comprised of members of the cardiac field who work toadvance cardiovascular ultrasound and strive to promote education,research, innovation, and service to the profession and public. Thisyear’s scientific session will be bringing in thousands of attendeesfrom the cardiovascular profession.
Ventripoint will be one of the sponsors for the 2022event and will have the opportunity to engage with thousands ofattendees though networking sessions, an in-person and virtualexhibit, poster presentations, and hands on educational workshops.
Ventripoint joining ASE 2022 through their sponsorshipopportunities will highlight the VMS+ and its new developments, engagewith new customers, and establish stronger relationships with existingcustomers.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.
For further information, pleasecontact:
Dr. George Adams
519-803-6937
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2022 TheNewswire - All rights reserved.